DiaMedica Non Currrent Assets Other vs Accounts Payable Analysis
DMAC Stock | USD 3.17 0.16 5.32% |
DiaMedica Therapeutics financial indicator trend analysis is much more than just examining DiaMedica Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether DiaMedica Therapeutics is a good investment. Please check the relationship between DiaMedica Therapeutics Non Currrent Assets Other and its Accounts Payable accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
Non Currrent Assets Other vs Accounts Payable
Non Currrent Assets Other vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of DiaMedica Therapeutics Non Currrent Assets Other account and Accounts Payable. At this time, the significance of the direction appears to have no relationship.
The correlation between DiaMedica Therapeutics' Non Currrent Assets Other and Accounts Payable is 0.06. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of DiaMedica Therapeutics, assuming nothing else is changed. The correlation between historical values of DiaMedica Therapeutics' Non Currrent Assets Other and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of DiaMedica Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Non Currrent Assets Other i.e., DiaMedica Therapeutics' Non Currrent Assets Other and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.06 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Accounts Payable
An accounting item on the balance sheet that represents DiaMedica Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of DiaMedica Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from DiaMedica Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into DiaMedica Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.At present, DiaMedica Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 92.8 M, whereas Issuance Of Capital Stock is forecasted to decline to about 22.7 M.
2023 | 2024 (projected) | Reconciled Depreciation | 28K | 21.7K | Interest Income | 44.9K | 47.1K |
DiaMedica Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
DiaMedica Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
DiaMedica Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 9.1M | 28.1M | 45.6M | 34.4M | 54.2M | 56.9M | |
Short Long Term Debt Total | 178K | 118K | 52K | 469K | 400K | 276.0K | |
Other Current Liab | 1.1M | 864K | 966K | 1.4M | 1.8M | 1.9M | |
Total Current Liabilities | 1.3M | 2.0M | 1.5M | 2.2M | 2.8M | 2.9M | |
Total Stockholder Equity | 7.6M | 26.0M | 44.0M | 31.8M | 51.1M | 53.6M | |
Property Plant And Equipment Net | 217K | 174K | 112K | 560K | 485K | 509.3K | |
Net Debt | (3.7M) | (7.3M) | (4.7M) | (4.3M) | (4.1M) | (4.4M) | |
Retained Earnings | (56.6M) | (68.9M) | (82.5M) | (96.2M) | (115.6M) | (109.8M) | |
Accounts Payable | 182K | 1.1M | 509K | 734K | 926K | 563.1K | |
Cash | 3.9M | 7.4M | 4.7M | 4.7M | 4.5M | 3.5M | |
Non Current Assets Total | 217K | 174K | 112K | 560K | 485.0K | 638.8K | |
Non Currrent Assets Other | 217K | 100K | (40.4M) | (1.0) | (0.9) | (0.94) | |
Cash And Short Term Investments | 7.9M | 27.5M | 45.1M | 33.5M | 52.9M | 55.5M | |
Net Receivables | 823K | 340K | 130K | 82K | 369K | 387.5K | |
Common Stock Shares Outstanding | 12.0M | 15.7M | 20.8M | 26.4M | 32.6M | 34.2M | |
Liabilities And Stockholders Equity | 9.1M | 28.1M | 45.6M | 34.4M | 54.2M | 56.9M | |
Other Stockholder Equity | 64.2M | 94.9M | 126.6M | 128.1M | 166.6M | 174.9M | |
Total Liab | 1.4M | 2.1M | 1.5M | 2.6M | 3.1M | 3.3M | |
Property Plant And Equipment Gross | 217K | 174K | 179K | 560K | 585K | 614.3K | |
Total Current Assets | 8.8M | 27.9M | 45.4M | 33.8M | 53.7M | 56.4M | |
Accumulated Other Comprehensive Income | 2K | (2K) | (51K) | (74K) | 6K | 5.7K | |
Short Term Debt | 60K | 65K | 49K | 69K | 83K | 70.5K | |
Other Current Assets | 47K | 64K | 84K | 251K | 411K | 431.6K | |
Net Tangible Assets | 17.0M | 7.6M | 26.0M | 44.0M | 50.6M | 53.2M | |
Short Term Investments | 4.0M | 20.1M | 40.4M | 28.8M | 48.4M | 50.8M | |
Property Plant Equipment | 217K | 74K | 112K | 560K | 644K | 676.2K | |
Capital Surpluse | 41.0M | 63.0M | 64.2M | 94.9M | 109.2M | 114.6M | |
Non Current Liabilities Total | 118K | 53K | 3K | 400K | 317K | 158.5K | |
Capital Lease Obligations | 178K | 118K | 52K | 469K | 400K | 420K | |
Net Invested Capital | 7.6M | 26.0M | 44.0M | 31.8M | 51.1M | 28.0M | |
Net Working Capital | 7.5M | 25.9M | 43.9M | 31.7M | 50.9M | 27.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Transaction History View history of all your transactions and understand their impact on performance |
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Return On Assets (0.30) | Return On Equity (0.47) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.